ATE267009T1 - Calciumrezeptoraktive moleküle - Google Patents

Calciumrezeptoraktive moleküle

Info

Publication number: ATE267009T1
Authority: AT; Austria
Prior art keywords: cell; cells; kidney; antagonist; patient
Prior art date: 1993-02-23

Application number

AT93907015T

Other languages

English (en)

Inventor

Edward F Nemeth

Edward M Brown

Steven C Hebert

Wagenen Bradford C Van

Manuel F Balandrin

Forrest H Fuller

Mar Eric G Del

Original Assignee

Brigham & Womens Hospital

Nps Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-23

Filing date

1993-02-23

Publication date

2004-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22236351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267009(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-02-23 Application filed by Brigham & Womens Hospital, Nps Pharma Inc filed Critical Brigham & Womens Hospital

2004-06-15 Application granted granted Critical

2004-06-15 Publication of ATE267009T1 publication Critical patent/ATE267009T1/de

Links

229910052791 calcium Inorganic materials 0.000 title 1
239000011575 calcium Substances 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 6
210000003292 kidney cell Anatomy 0.000 abstract 3
239000005557 antagonist Substances 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
229910001410 inorganic ion Inorganic materials 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
210000003771 C cell Anatomy 0.000 abstract 1
102400000921 Gastrin Human genes 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000001174 ascending effect Effects 0.000 abstract 1
230000001746 atrial effect Effects 0.000 abstract 1
210000001772 blood platelet Anatomy 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000002615 epidermis Anatomy 0.000 abstract 1
210000002406 gastrin-secreting cell Anatomy 0.000 abstract 1
210000001511 glucagon-secreting cell Anatomy 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
210000002510 keratinocyte Anatomy 0.000 abstract 1
210000004216 mammary stem cell Anatomy 0.000 abstract 1
210000003584 mesangial cell Anatomy 0.000 abstract 1
210000002997 osteoclast Anatomy 0.000 abstract 1
230000000849 parathyroid Effects 0.000 abstract 1
210000002826 placenta Anatomy 0.000 abstract 1
210000000512 proximal kidney tubule Anatomy 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
210000001685 thyroid gland Anatomy 0.000 abstract 1
210000002993 trophoblast Anatomy 0.000 abstract 1
210000005239 tubule Anatomy 0.000 abstract 1
210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cell Biology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)

AT93907015T 1993-02-23 1993-02-23 Calciumrezeptoraktive moleküle ATE267009T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1993/001642 WO1994018959A1 (en)	1993-02-23	1993-02-23	Calcium receptor-active molecules

Publications (1)

Publication Number	Publication Date
ATE267009T1 true ATE267009T1 (de)	2004-06-15

Family

ID=22236351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93907015T ATE267009T1 (de)	1993-02-23	1993-02-23	Calciumrezeptoraktive moleküle

Country Status (8)

Country	Link
EP (1)	EP0637237B1 (de)
JP (1)	JP4143118B2 (de)
KR (1)	KR100296899B1 (de)
AT (1)	ATE267009T1 (de)
AU (1)	AU3777093A (de)
DE (1)	DE69333527T2 (de)
RU (1)	RU2146132C1 (de)
WO (1)	WO1994018959A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6313146B1 (en)	1991-08-23	2001-11-06	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5858684A (en) *	1991-08-23	1999-01-12	The Brigham And Women's Hospital, Inc.	Method of screening calcium receptor-active molecules
US5688938A (en) *	1991-08-23	1997-11-18	The Brigham & Women's Hospital, Inc.	Calcium receptor-active molecules
US6031003A (en) *	1991-08-23	2000-02-29	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
CN1192011C (zh) *	1991-08-23	2005-03-09	Nps药物有限公司	对钙受体具活性的芳烷基胺化合物
US5763569A (en) *	1991-08-23	1998-06-09	The Brigham And Women's Hospital, Inc	Calcium receptor-active molecules
US5962314A (en) *	1993-02-23	1999-10-05	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5852041A (en) *	1993-04-07	1998-12-22	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acethylcholine receptors
CN100558698C (zh) *	1994-10-21	2009-11-11	Nps药物有限公司	钙受体活性化合物
ES2285707T3 (es)	1994-10-21	2007-11-16	Nps Pharmaceuticals, Inc.	Compuestos activos frente al receptor de calcio.
US5824550A (en) *	1994-10-28	1998-10-20	Barnes-Jewish Hopital	Voltage-gated calcium channel and antisense oligonucleotides thereto
US6060604A (en) *	1995-03-31	2000-05-09	Florida State University	Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
US5585388A (en) *	1995-04-07	1996-12-17	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
ES2308779T3 (es)	1995-07-26	2008-12-01	Astrazeneca Ab	Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
US5794887A (en)	1995-11-17	1998-08-18	Komerath; Narayanan M.	Stagnation point vortex controller
US6818660B2 (en)	1996-04-09	2004-11-16	Nps Pharmaceuticals, Inc.	Calcilytic compounds
DE69733649T2 (de)	1996-04-09	2006-05-18	NPS Pharmaceuticals, Inc., Salt Lake City	Calcylitische verbindungen
EP1770083B1 (de) *	1996-05-01	2009-04-29	Nps Pharmaceuticals, Inc.	Inorganische am Ionen-Rezeptor aktive Verbindungen
WO1997041090A1 (en)	1996-05-01	1997-11-06	Nps Pharmaceuticals, Inc.	Inorganic ion receptor-active compounds
WO1997042951A1 (en)	1996-05-16	1997-11-20	Board Of Regents, The University Of Texas System	Methods of identifying modulators of perivascular sensory nerve ca2+ receptors
CN1131202C (zh)	1996-07-08	2003-12-17	麒麟麦酒株式会社	钙受体活性化合物
US7202261B2 (en)	1996-12-03	2007-04-10	Nps Pharmaceuticals, Inc.	Calcilytic compounds
TW483881B (en)	1996-12-03	2002-04-21	Nps Pharma Inc	Calcilytic compounds
DE19805370A1 (de) *	1997-03-14	1998-09-17	Gruenenthal Gmbh	Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
US6083480A (en)	1997-05-01	2000-07-04	Diatide, Inc.	Calcitonin receptor binding reagents
WO1999005161A1 (en)	1997-07-25	1999-02-04	Ligand Pharmaceuticals Incorporated	HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU2351699A (en) *	1998-01-30	1999-08-16	Brigham And Women's Hospital	The human calcium-sensing receptor in the detection and treatment of cancer
TWI245035B (en) *	1998-06-26	2005-12-11	Ono Pharmaceutical Co	Amino acid derivatives and a pharmaceutical composition comprising the derivatives
CA2347092A1 (en)	1998-10-14	2000-04-20	Ortho-Mcneil Pharmaceutical, Inc.	1,2-disubstituted cyclopropanes
DE19924148A1 (de) *	1999-05-26	2000-12-07	Univ Heidelberg	Sphingomyelinasehemmer
RU2196338C1 (ru) *	2002-01-28	2003-01-10	Акционерное общество открытого типа "Информационные телекоммуникационные технологии"	Способ измерения параметров погруженных в поглощающую среду антенн методом масштабного моделирования, способ приготовления вещества для моделирования поглощающей среды и композиция для приготовления вещества для моделирования поглощающей среды
US7176322B2 (en)	2002-05-23	2007-02-13	Amgen Inc.	Calcium receptor modulating agents
US6908935B2 (en)	2002-05-23	2005-06-21	Amgen Inc.	Calcium receptor modulating agents
US20040081970A1 (en) *	2002-10-28	2004-04-29	Athersys, Inc.	Calcium-sensing receptor 2 (CaR2) and methods for using
WO2004069793A2 (en)	2003-01-28	2004-08-19	Bristol-Myers Squibb Company	Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en)	2003-02-12	2007-04-17	Bristol-Myers Squibb Company	Thiazolidine compounds as calcium sensing receptor modulators
RU2241474C1 (ru) *	2003-04-14	2004-12-10	Скаткин Михаил Георгиевич	Препарат из плаценты и способ его получения
US7265145B2 (en)	2003-05-28	2007-09-04	Bristol-Myers Squibb Company	Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
PT3395338T (pt)	2003-09-12	2019-07-23	Amgen Inc	Formulação de dissolução rápida de cinacalcet hcl
WO2005065050A2 (ja)	2003-12-25	2005-07-21	Asahi Kasei Pharma Corporation	２環化合物
ES2561111T3 (es)	2004-05-28	2016-02-24	Mitsubishi Tanabe Pharma Corporation	Arilalquilaminas y procedimiento para la producción de las mismas
US7361789B1 (en)	2004-07-28	2008-04-22	Amgen Inc.	Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US7585886B2 (en)	2005-05-19	2009-09-08	Astellas Pharma Inc.	Pyrrolidine derivative or salt thereof
US8486381B2 (en)	2005-09-02	2013-07-16	Amgen Inc.	Methods of modulating intestinal fluid balance
WO2007055388A2 (en) *	2005-11-09	2007-05-18	Ajinomoto Co., Inc.	Calcium receptor activator
MX2008012061A (es)	2006-03-23	2008-12-17	Amgen Inc	Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
EP2010150A2 (de)	2006-04-20	2009-01-07	Amgen Inc.	Stabile emulsionsformulierungen
WO2008059854A1 (en) *	2006-11-16	2008-05-22	Astellas Pharma Inc.	Piperidine derivatives or salts thereof
CA2681582C (en)	2007-03-30	2015-07-14	Amgen Inc.	Methods of treating bowel disorders
ES2476391T3 (es) *	2007-10-15	2014-07-14	Amgen Inc.	Agentes moduladores de receptor de calcio
CA2710039C (en)	2007-12-26	2018-07-03	Critical Outcome Technologies, Inc.	Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2113257A1 (de) *	2008-04-30	2009-11-04	Consorzio per il Centro di Biomedica Moleculare Scrl	Polyelektrolyt mit positiver Überschussladung zur Verwendung als Medikament und Diagnose von Krebs
EP2318406B1 (de)	2008-07-17	2016-01-27	Critical Outcome Technologies, Inc.	Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
ES2332636B1 (es) *	2008-08-06	2011-02-10	Universitat De Les Illes Balears	Composicion de liquido de dialisis.
WO2010021351A1 (ja)	2008-08-22	2010-02-25	第一三共株式会社	シクロアルキルアミン誘導体
WO2010103429A1 (en)	2009-03-10	2010-09-16	Pfizer Inc.	1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2010104882A1 (en)	2009-03-10	2010-09-16	Amgen Inc.	Methods of modulating sperm motility
EP2435400A2 (de)	2009-05-27	2012-04-04	Leo Pharma A/S	Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung
US8765676B2 (en)	2009-05-27	2014-07-01	Leo Pharma A/S	Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) *	2009-06-25	2010-12-29	第一三共株式会社	インドリン誘導体
RU2619185C2 (ru) *	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
CA2785832A1 (en) *	2010-01-04	2011-07-07	Curna, Inc.	Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2552915B1 (de)	2010-04-01	2017-07-19	Critical Outcome Technologies Inc.	Verbindungen zur behandlung von hiv
WO2011127337A2 (en) *	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2012000498A1 (en)	2010-06-30	2012-01-05	Leo Pharma A/S	New polymorphic form of a calcimimetic compound
JP5968881B2 (ja)	2010-06-30	2016-08-10	レオファーマアクティーゼルスカブ	カルシウム模倣化合物の新規多形
EP2643292A1 (de)	2010-11-26	2013-10-02	Leo Pharma A/S	Casr-aktive verbindungen
JP2014500882A (ja)	2010-11-26	2014-01-16	レオファーマアクティーゼルスカブ	カルシウム感知受容体活性化合物
JP2014508103A (ja)	2010-11-26	2014-04-03	レオファーマアクティーゼルスカブ	カルシウム感知受容体活性化合物
WO2012069420A2 (en)	2010-11-26	2012-05-31	Leo Pharma A/S	Calcium-sensing receptor-active compounds
EP2705830A1 (de) *	2012-09-05	2014-03-12	Laboratoire In'Oya SAS	Verwendung von Spinnengiften zur Hautweißung/Depigmentierung, und Zusammensetzung mit Spinnengiftderivaten
GB201217330D0 (en)	2012-09-28	2012-11-14	Univ Cardiff	Therapeutic for treating inflammatory lung disorders
RU2552300C2 (ru) *	2013-10-23	2015-06-10	Государственное бюджетное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздрава Российской Федерации	Способ коррекции состояния костной ткани и профилактики возникновения переломов у больных с сердечно-сосудистыми заболеваниями

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4591605A (en) *	1981-11-10	1986-05-27	Research Foundation Of State University Of New York	Method and ingestible formulation for inhibiting the secretion of stomach acid
HU200591B (en) *	1986-07-11	1990-07-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US5021551A (en) *	1989-01-18	1991-06-04	Washington University	Method of enhancing peptide immunogenicity
DD298412A5 (de) *	1989-04-28	1992-02-20	��@��Kk��	Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
EP0597830A1 (de) *	1989-07-03	1994-05-25	New York University Nyu Medical Center	Verwendung von Polyaminen als die Ionenkanäle regulierenden Wirkstoffe
US5312928A (en) *	1991-02-11	1994-05-17	Cambridge Neuroscience	Calcium channel antagonists and methodology for their identification
ATE313321T1 (de) *	1991-08-23	2006-01-15	Nps Pharma Inc	Kalzium-rezeptor aktive verbindungen

1993
- 1993-02-23 DE DE69333527T patent/DE69333527T2/de not_active Expired - Lifetime
- 1993-02-23 WO PCT/US1993/001642 patent/WO1994018959A1/en not_active Ceased
- 1993-02-23 JP JP50994894A patent/JP4143118B2/ja not_active Expired - Lifetime
- 1993-02-23 AT AT93907015T patent/ATE267009T1/de not_active IP Right Cessation
- 1993-02-23 KR KR1019940701319A patent/KR100296899B1/ko not_active Expired - Lifetime
- 1993-02-23 RU RU94036778A patent/RU2146132C1/ru active Protection Beyond IP Right Term
- 1993-02-23 AU AU37770/93A patent/AU3777093A/en not_active Abandoned
- 1993-02-23 EP EP93907015A patent/EP0637237B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU3777093A (en)	1994-09-14
HK1012560A1 (en)	1999-08-06
RU94036778A (ru)	1996-05-20
WO1994018959A1 (en)	1994-09-01
RU2146132C1 (ru)	2000-03-10
EP0637237B1 (de)	2004-05-19
JP4143118B2 (ja)	2008-09-03
JPH07506380A (ja)	1995-07-13
DE69333527T2 (de)	2005-06-16
KR100296899B1 (ko)	2001-10-24
EP0637237A1 (de)	1995-02-08
DE69333527D1 (de)	2004-06-24

Legal Events

Date	Code	Title	Description
2004-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE267009T1 (de)	2004-06-15	Calciumrezeptoraktive moleküle
DK1281702T3 (da)	2006-04-18	Calciumreceptoraktive molekyler
Jozsa et al.	1988	Quantitative alterations in intramuscular connective tissue following immobilization: an experimental study in the rat calf muscles
Nilvebrant et al.	1997	Tolterodine–a new bladder-selective antimuscarinic agent
Nobuo et al.	1987	Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay
Eakins et al.	1970	Antagonism of some smooth muscle actions of prostaglandins by polyphloretin phosphate
DE69828603D1 (de)	2005-02-17	Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten
SI9111227B (sl)	2000-12-31	Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic
CY1109827T1 (el)	2014-09-10	Χρηση της αλλαντοτοξινης για την αγωγη δυσκολα αντιμετωπισιμης δυσλειτουργιας κενωσης
DE19675039I2 (de)	2003-01-09	Bis-dimethoxymethyl(trimethox-ybenzyl)isochinolinium-Salze ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EA199800752A1 (ru)	1999-04-29	Пентафторбензолсульфонамиды и их аналоги
Becker et al.	1999	12-year outcome after modified Watson-Jones tenodesis for ankle instability.
EA199900756A1 (ru)	2000-08-28	Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия
ATE16191T1 (de)	1985-11-15	Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten.
DE60144574D1 (de)	2011-06-16	Absorptionsmittel, verfahren zu dessen herstellung und das absorptionsmittel umfassender absorbierender gegenstand
DE69200045D1 (de)	1994-03-17	Thiazolopyrimidinderivate als Angiotensin-II-Rezeptorantagonisten: Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
KR970006281A (ko)	1997-02-19	치환된 신남산 구아니디드, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제
Usui et al.	1979	Successful replantation of an amputated leg in a child
ATE8739T1 (de)	1984-08-15	Pharmazeutische zubereitungen.
UA41329C2 (uk)	2001-09-17	Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
SU1162420A1 (ru)	1985-06-23	Способ восстановлени разгибательного аппарата пальца кисти на уровне проксимального межфалангового сустава
TW360629B (en)	1999-06-11	Calcium receptor active molecules
ATE120464T1 (de)	1995-04-15	Acylaminoalkylidenhydroxybisphosphonsäure brauchbar in der therapie von osteoartikularen krankheiten.
FREUNDLICH	1984	Unusual fracture of the distal radius
SU1641299A1 (ru)	1991-04-15	Способ внесуставного устранени нестабильности в коленном суставе при разрыве передней крестообразной св зки